Lilly to acquire Protomer Technologies for $1B

By The Science Advisory Board staff writers

July 14, 2021 -- Eli Lilly will acquire private biotechnology firm Protomer Technologies for an estimated $1 billion.

Protomer engineers next-generation protein therapies that can sense molecular activators in the body. Its chemical biology-based platform enables the development of therapeutic peptides and proteins, including glucose-responsive insulins, with tunable activity that can be controlled with small molecules.

The potential value of the transaction could total more than $1 billion with future development and commercial milestones.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.